BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » RoosterBio » Page 2

RegMed’s First Xeno-Free Human Mesenchymal Stem Cell (MSC) Cell Banks

May 30, 2017 By Cade Hildreth (CEO) Leave a Comment

RoosterBio

RoosterBioRoosterBio has announced the launch of the Regenerative Medicine (RM) industry’s first xeno-free (XF) hMSC cell banks to advance and simplify stem cell biomanufacturing. By incorporating XF starting materials at early stages, RM scientists can perform more clinically relevant work, resulting in an expedited path towards clinical testing programs. Due of the importance of this announcement, I followed up with Dr. Priya Baraniak, Director of BD & Strategic Marketing at RoosterBio, to further explore details of the launch.  [Read more…]

Filed Under: Interviews, MSCs Tagged With: cell bank, MSC, regenerative medicine, RoosterBio

RoosterBio Launches Xeno-Free hMSC Cell Banks to Advance Stem Cell Biomanufacturing

May 4, 2017 By Cade Hildreth (CEO) Leave a Comment

RoosterBio Launches First Xeno-Free hMSC Cell Banks

RoosterBio Launches the Regenerative Medicine Industry’s First Xeno-Free hMSC Cell Banks to Advance and Simplify Stem Cell Biomanufacturing

RoosterBioFREDERICK, MARYLAND, May 04, 2017–At a CAGR of 23.2% and estimated revenue of $68B by 2020, the Regenerative Medicine (“RM”) industry continues to call for new tools designed to accelerate this aggressive growth. Based on strong RM market demand, RoosterBio Inc today announces the launch of xeno-free (“XF”) human bone-marrow derived mesenchymal stem/stromal cell (hMSC) products.

[Read more…]

Filed Under: MSCs, Press Releases, Stem Cells Tagged With: cell banks, hMSC, regenerative medicine, RoosterBio, xeno-free

GenCure, StemBioSys Forge Stem Cell Product Manufacturing Agreement

January 30, 2017 By Cade Hildreth (CEO) Leave a Comment

Gencure StemBioSys

GenCure will be exclusive producer for StemBioSys-developed regenerative medicine products

StemBioSys

January 30, 2017, SAN ANTONIO – GenCure, a subsidiary of San Antonio-based biotech BioBridge Global, has entered a development and manufacturing agreement with stem cell technology developer StemBioSys Inc. of San Antonio. [Read more…]

Filed Under: Cord Blood, HSCs, Press Releases, Stem Cells Tagged With: Biobridge Global, cord blood, GenCure, RoosterBio, StemBioSys

RoosterBio Releases Universal Bioprocess Bags to Streamline Closed System Stem Cell Production

December 8, 2016 By Cade Hildreth (CEO) Leave a Comment

RoosterBio hMSC

RoosterBioRoosterBio is an innovative mesenchymal stem cell (MSC) company that is focusing on democratizing stem cell manufacturing and ushering in a new era of regenerative medicine.  2016 has been a massive year for the company, as it recently announced a collaboration with BioBridge Global, as well as a co-branding partnership with the global filtration, separation and purification leader, Pall Corporation. [Read more…]

Filed Under: MSCs Tagged With: hMSC, Jon Rowley, RoosterBio

Pall Corporation and RoosterBio to Co-Market Mesenchymal Stem/Stromal Cells and Bioreactors

October 5, 2016 By Cade Hildreth (CEO) Leave a Comment

RoosterBio and Pall to Collaborate

The agreement will encompass a co-development and marketing partnership.

RoosterBio, "Radically Changing the Use of Stem Cells" - Logo
RoosterBio, “Radically Changing the Use of Stem Cells”

OCTOBER 05, 2016 –Pall Corporation, a global leader in bioprocess equipment and disposables, announced the signing of a commercial collaboration agreement with RoosterBio Inc, an innovative adult stem cell technology company. The agreement will encompass a co-development and marketing partnership, delivering complete solutions for industrial-scale bioreactor expansion of human Mesenchymal Stem/Stromal Cells (hMSCs). [Read more…]

Filed Under: MSCs Tagged With: cell manufacturing, mesenchymal, Pall Corporation, RoosterBio

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.